The optimal duration of tuberculosis treatment for persons infected with human immunodeficiency virus (HIV) has been debated. A cohort of 4571 culture-positive drug-susceptible patients who received у24 weeks of standard 4-drug tuberculosis treatment were assessed to determine the incidence of tuberculosis relapse. Tuberculosis "recurrence" was defined as having a positive culture !30 days after the last treatment date and "relapse" as having a positive culture у30 days after the last treatment. Patients infected with HIV were more likely than those who were uninfected to have recurrence or relapse (2.0 vs. 0.4 per 100 person-years, P ! ). Patients infected with HIV who received р36 weeks of treatment were more likely than those who .001 received 136 weeks to have a recurrence (7.9% vs.
sons coinfected with HIV has not been clearly defined. A number of recent studies among HIV-infected patients with TB that used 6-month drug regimens concluded that treatment failure and relapse rates in persons infected with HIV were not significantly different when compared with uninfected patients [7] [8] [9] [10] . In all of those studies, however, the relapse rate was higher in the HIV-infected group.
HIV was a significant contributor to the recent TB epidemic in New York City (NYC); nearly one-third of NYC's TB patients were coinfected with HIV [11, 12] . In response to the epidemic, improvements were instituted in NYC's Tuberculosis Control Program beginning in 1992 that included intensive case management of all TB patients, to ensure appropriate treatment and timely completion. Increased use of directly observed treatment, as well as other measures, resulted in a dramatic improvement in the proportion of patients who completed treatment and a decreasing incidence of TB during each subsequent year [13, 14] . During those years, the treatment for HIV-infected patients with TB, as recommended by the NYC Tuberculosis Control Program, was a 9-month regimen that consisted of 2 months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by 7 months of H and R [15] . In order to determine the incidence of TB relapse among patients under our program conditions and to describe factors associated with relapse, we reviewed the treatment outcome of a cohort of patients who were infected or uninfected with HIV and those with unknown HIV status.
METHODS
This was a retrospective cohort study. The cohort of TB patients included those whose diagnosis was verified from 1 January 1993 through 30 June 1996 in NYC. Patients who met the following criteria were retained in the analyses: (1) having a positive culture for Mycobacterium tuberculosis; (2) having an initial M. tuberculosis isolate that was susceptible to H, R, and Z; and (3) receiving at least 6 months of treatment with у2 antituberculous medications. Patients who died or were lost before completing at least 6 months of treatment were excluded from the analyses.
The outcome variable we studied was having a positive M. tuberculosis culture after receiving at least 6 months of anti-TB treatment (defined hereafter as an "event"). Patients were further classified into 1 of the 2 following groups. "Recurrence" was defined as having a positive culture within 30 days after the last treatment date. "Relapse" was defined as having a positive culture у30 days after the last treatment date. Demographic, clinical, and treatment characteristics of patients were analyzed to determine which factors were associated with these outcomes.
Patient information was obtained from the TB case registry, which contains demographic, treatment, bacteriologic, and outcome information on all suspected and confirmed TB cases. Follow-up was performed through active surveillance of mycobacteriology laboratories for positive M. tuberculosis cultures. In addition, monthly audits of all laboratories were conducted to identify positive cultures missed through the ongoing surveillance. Furthermore, the NYC health code stipulates mandatory reporting of each positive M. tuberculosis culture to the TB control program within 24 h of identification. In order to identify death that occurred after patients completed treatment, the study cohort was matched to the NYC death registry on 31 August 1999. The last date of follow-up was defined as the date of relapse, the date of death, or 31 August 1999, whichever was earliest.
Type of treatment was defined according to the following regimens: (1) at least 8 weeks of H, R, and Z followed by 16 weeks of H and R (2HRZ/4HR); (2) at least 8 weeks of H, R, and Z followed by at least 24 weeks of H and E; (3) at least 36 weeks of H and R but !8 weeks of Z; or (4) other regimens (grouped as "other"). Adherence on directly observed therapy (DOT) was defined on the basis of the average of monthly compliance. Patients were considered adherent to DOT if у80% of total expected doses were observed. Adherence to self-administered therapy was defined as no gap 12 weeks in treatment during self-administered treatment. The number of weeks of initial treatment was the period from the date treatment with у2 anti-TB drugs was started to the date of the last dose. Treatment duration was examined as a continuous variable and as a categorical variable by use of probability plots and quartiles. For the multivariate analyses, an indicator variable for duration of initial treatment was defined that used 36 weeks as a cutoff. During the study period, DNA fingerprinting was performed by use of standard techniques on selected patient isolates as part of periodic surveys to assess clustering or during the course of patient care and outbreak investigations [16, 17] .
Statistical analysis. Patients who had a recurrence or relapse were compared with patients who did not have a recurrence or relapse by using selected demographic, clinical, and treatment characteristics. The rate of relapse per 100 personyears of follow-up was computed. In addition, HIV-positive patients were compared with patients who were HIV-negative and patients whose HIV serostatus was unknown. Risk ratios (RRs) and 95% CIs were computed. Categorical variables were compared by use of the Pearson x 2 test. Fisher's exact CIs were used when expected cell values were !5. Continuous variables were compared by use of Student's t test or the Wilcoxon ranksum test for nonparametric data. Proportional hazards and logistic regression models were used to assess factors that were independently associated with recurrence or relapse by use of SPSS (Version 10.0, SPSS, Inc.) and SAS software (Release 7, SAS Institute, Inc.). Significance levels were set at . In P ! .05 the multivariate analysis, we included as predictor variables all the variables that were significantly associated with the outcome variables in the univariate analysis. In the univariate analysis, we also assessed whether having a positive culture during the fifth or sixth months of treatment was a risk factor for recurrence or relapse. To evaluate possible similarities between these patients and patients with recurrence, we repeated the univariate and multivariate analyses, having reclassified patients who were culture-positive during the fifth and sixth months of treatment as having recurrence.
RESULTS
The cohort included 4571 patients; 1530 (33%) were infected with HIV, 1413 (31%) were uninfected with HIV, and 1628 (36%) had unknown HIV serostatus. Of the 4571 patients, 53 (1.2%) had a recurrence and 70 (1.5%) relapsed. were significantly less likely than nonevent patients to be Asian and to have only pulmonary disease. A history of drug use, having been born in the United States, having both pulmonary and extrapulmonary disease and sputum positive for acid-fast bacilli on smear microscopy, and HIV infection were significantly associated with an increased risk of an event. Having a positive culture in the fifth or sixth month of treatment and nonadherence were significantly associated with an increased risk of recurrence or relapse.
Patients infected with HIV differed significantly from patients uninfected with HIV on many of the variables examined. Those infected with HIV were more likely than those uninfected to be male (73% vs. 61%, ), of black race (62% vs. 41%, ). P ! .01 Of the 123 event patients, 95 selected patients had susceptibility testing of the recurrence or relapse isolate; 26 (27%) of these had drug resistance to H or R at time of recurrence or relapse. Of these, 12 (46%) had R monoresistance, 5 (19%) had resistance to H only, and 9 (35%) had resistance to both H and R (MDR). Fourteen (53%) of these 26 were nonadherent; 15 (57%) received DOT. Patients who developed drug resistance did not significantly differ from patients who had drug-susceptible relapse isolates in the proportion who received DOT or who were nonadherent. Only 1 patient who relapsed with MDR TB had received the entire course of treatment on DOT. Restriction-fragment length polymorphism results were available for 15 (58%) of 26 patients who had drug resistant isolates at time of relapse and 21 (22%) of 97 patients whose isolate remained drug susceptible. Two of the isolates with drug resistance had a DNA strain that was associated with a large outbreak [18] . Two additional patients, for whom DNA analysis n p 30 n p 2266 c 2HRZ/4HR, isoniazid and rifampin and pyrazinamide or ethambutol for у2 months and followed by isoniazid and rifampin for у4 months.
was not available, showed the resistance pattern characteristic of this strain. These 4 cases are considered to have resulted from exogenous reinfection.
The median number of weeks from start of initial treatment to recurrence was 37 (range, 26-96 weeks). Less than 2% of patients received 24-26 weeks of treatment. Among patients who relapsed, the median weeks from the end of the initial treatment to relapse was 36 (range, 4-218 weeks). During the study period, the proportion of patients receiving any DOT increased significantly each year among event (from 47% to 100%) and nonevent patients (from 34% to 70%). Among patients who received any DOT during the initial treatment, patients who relapsed did not differ from nonrelapse patients according to the median number of weeks of DOT received. The median number of weeks on DOT was 21 weeks.
Among the 3255 patients who received a minimum of the standard R-containing regimen (2HRZ[E]/4HR), recurrence and relapse rates were computed for patients who received р36 weeks and 136 weeks stratified by HIV status. These are shown in figure 2. Recurrence was significantly more likely in patients infected with HIV who received р36 weeks of treatment compared with patients infected with HIV who received 136 weeks of treatment (12 [ Recurrence and relapse by weeks of initial treatment and HIV status. Note: includes only patients who received the standard treatment regimen (isoniazid and rifampin and pyrazinamide or ethambutol for 2 months, followed by isoniazid and rifampin for at least 4 months). NOTE. Data are patients who received isoniazid and rifampin and pyrazinamide or ethambutol for у2 months followed by isoniazid and rifampin for у4 months. AFB, acid-fast bacilli; TB, tuberculosis.
a Adjusted for drug abuse, positive culture in the fifth or sixth month, nonadherence, and directly observed treatment.
recurrence and 1 (0.2%) relapsed; duration of treatment did not have a significant effect on recurrence or relapse.
In multivariate logistic regression analysis, HIV infection, having both pulmonary and extrapulmonary disease, a history of drug use, nonadherence to TB treatment, initial treatment р36 weeks, and birth in the United States were independently associated with having an event among patients who received the minimum standard short-course regimen (table 3) . Because of the differences observed in recurrence and relapse rates by HIV serostatus in the bivariate analysis, we also examined recurrence and relapse separately by HIV serostatus in multivariate models. Among patients infected with HIV, having both pulmonary and extrapulmonary disease, a history of drug use, nonadherence to TB treatment, and initial treatment р36 weeks were independently associated with recurrence (table 4) . Among patients uninfected HIV, only treatment р36 weeks was independently associated with recurrence. Among persons with unknown HIV serostatus, none of the variables were independently associated with recurrence or relapse. None of the variables examined were independently associated with relapse regardless of HIV serostatus. When we excluded the 4 patients with exogenous reinfection, having both pulmonary and extrapulmonary disease was no longer significantly associated with recurrence.
DISCUSSION
In contrast to the conclusions drawn from recent studies comparing failure and relapse rates in HIV-infected and HIV-uninfected patients with TB treated with 6-month regimens [7] [8] [9] [10] , our findings show that HIV-infected patients with TB in NYC were significantly more likely to have a recurrence of a positive culture and to relapse than HIV-uninfected patients or than persons with unknown HIV serostatus. This finding is not entirely unexpected. Each of the previous studies had higher failure and relapse rates in HIV-infected patients with TB compared with HIV-uninfected patients. Kassim et al. [7] found a relapse rate of 4.6% in patients infected with HIV compared with 3% among HIV-uninfected patients in West Africa. Chaisson et al. [8] showed that 5.4% of patients infected with HIV relapsed, compared with 2.8% of HIV-uninfected patients in Haiti. Perriens et al. [9] reported a 9% relapse rate among patients infected with HIV in Zaire compared with 5.3% in HIV-uninfected patients. Sterling et al. [10] reported 6.4% relapse in HIV-infected and 5.5% in HIV-uninfected patients treated in Baltimore. The number of patients in these studies ranged from 47 to 653 HIV-infected patients and 127 to 282 HIV-uninfected patients. It is possible these studies did not NOTE. Data are patients who received isoniazid and rifampin and pyrazinamide or ethambutol for у2 months followed by isoniazid and rifampin for у4 months. TB, tuberculosis.
a Adjusted for country of birth, positive culture in the fifth or sixth month, and acid-fast bacilli smear positive in first 30 days.
have sufficient power to detect a statistically significant difference between groups. A possible effect of duration of treatment in persons infected with HIV in our study, however, was not expected. Patients infected with HIV who received !36 weeks of treatment were at increased risk of recurrence of a positive culture within 30 days after treatment completion in our analyses. Perriens et al. [9] reported that, among patients infected with HIV, a 52-week regimen reduced the risk of relapse compared with a 24-week regimen. In that study, relapse was defined by evidence of TB in a patient who had had no such evidence at the completion of the 6-month course [9] . Two prospective studies among HIV-infected patients with TB found higher relapse rates when a 24-week regimen was used [19, 20] . One [19] showed a slightly higher relapse rate among persons infected with HIV who were treated with a 24-week regimen compared with those treated for 36 weeks (3.9% vs. 2%), although the difference was not statistically significant. Relapse in that study was defined by a positive culture after the patient's sputum culture had converted to negative or the patient's symptoms had resolved and the patient had completed treatment [19] . In the second study [20] , HIV-infected patients with TB in the control arm received a standard 24-week regimen with twice weekly H/R in the continuation phase. Three (9.6%) of 31 patients relapsed. Our data showed no difference in relapse rates (defined as positive culture 130 days after treatment completion) for patients who received !37 weeks of treatment compared with patients who received 137 weeks of treatment. We studied recurrence in our analysis because a significant number of patients were culture positive after completing at least 24 weeks of treatment. These findings underscore the importance of ensuring cure at the end of treatment. A medical assessment of HIV-infected patients with TB 3 months after treatment completion is indicated. It is not likely that the use of highly active antiretroviral treatment (HAART) had an effect on these observations, because HAART became widely used after the period we studied. Data collected in our program for patients infected with HIV diagnosed during the period of July 1996 through June 1997 showed that few TB patients (11%) were receiving HAART while on TB treatment [unpublished data, New York City Department of Health]. In addition, because relapse rates for persons infected with HIV did not change significantly over the study period, it is not likely that HAART had an effect on TB relapse rates.
The overall risk of recurrence and relapse was low in both HIV-infected and -uninfected patients who used a R-containing regimen under our program conditions with high use of directly observed therapy. However, the low rates we observed in our analysis are not directly comparable to those seen in studies of shorter treatment duration because the majority of patients received у36 weeks of initial treatment. Longer duration of initial treatment of our study patients is the most likely explanation for the low rates seen in our study compared with rates reported in the studies of 24-week regimens. In addition, we included only patients with culture-confirmed initial episode in which the isolate was susceptible to at least I and R, and we defined recurrence and relapse on the basis of positive culture. Three of the studies mentioned elsewhere [7, 9, 10] included culture-negative patients; in one [9] , 18% of patients had initial resistance to H.
Additional characteristics that were independently associated with recurrence among persons infected with HIV were nonadherence, drug use, and having both pulmonary and extrapulmonary disease. The role of nonadherence in poor outcomes has been documented by a number of investigators [21] [22] [23] . The role of illicit drug use among patients who relapse is less well understood. Some authors have reported decreased survival among injection drug users with TB and have suggested that decreased survival may result from a higher incidence of bacterial infections in this group [24] . Having both pulmonary and extrapulmonary disease sites may be a reflection of severity of HIV disease. Unfortunately, we did not have information on the level of immune compromise in our patients.
A significant number of patients had drug resistance to either H, R, or both at the time of recurrence or relapse. Although 3 relapses and 1 recurrence probably resulted from exogenous reinfection with a drug-resistant strain, the likelihood of reinfection among the remaining cases is unknown. The others most likely represent acquired resistance, given that one-half of the patients who relapsed with drug resistance were nonadherent. In our study, only 1 of the 9 patients who relapsed with a MDR isolate received initial treatment entirely on DOT. An increased risk of R monoresistance has been observed by us and also reported by other investigators in patients with advanced HIV infection. In some cases, primary resistance associated with recent transmission was seen; in others, R monoresistance was acquired during the course of treatment [25, 26] .
Our findings are limited by a number of factors. It is possible that some underascertainment of cases occurred because we relied on surveillance of laboratories to identify cases rather than follow-up directly with patients to identify recurrence or relapse. Some patients could have moved out of NYC before a recurrence or relapse occurred. This would have resulted in an underestimation of the rate of recurrence or relapse. However, the level of ascertainment of positive cultures in NYC is high [12] . Mandatory reporting of each positive M. tuberculosis culture within 24 h of identification is reinforced through active surveillance for M. tuberculosis cultures in all mycobacteriology laboratories and monthly laboratory audits to identify any cultures missed through routine surveillance. During the study period, !1% of cases were not identified through this process [12] . The number of patients who move out of NYC before having an event is also likely to be low and unlikely to significantly change the findings. The average fraction of patients who move during TB treatment is ∼4% (Tuberculosis Control Program, New York City Department of Health, unpublished data). Even if we assumed that the same proportion of patients left the city during the first 2 years after treatment and applied a relapse rate of 2.7%, the number of undetected cases would be 5. This would raise the relapse rate during the study period from 2.7% to 2.8%. Another limitation was the lack of information about the severity of HIV disease. A prospective study of patients with TB and HIV infection [24] showed that severity of immunodeficiency was independently associated with reduced survival. Severity of HIV illness may be a better predictor of recurrence or relapse than HIV infection.
The absence of a comparison group of patients who received 6 months of treatment also limited our analyses. Although examination of the difference in recurrence and relapse rates for patients who received 24 weeks of initial treatment would be useful, the small number of patients who received this regimen precluded such analysis. Even though national guidelines for treating patients infected with HIV were modified in 1994 from a 36-week to a 24-week regimen, providers may have been cautious about providing the short-course treatment during the early years of the epidemic, particularly among patients with extrapulmonary disease or in whom HIV serostatus was uncertain. In fact, local treatment guidelines recommended use of the 36-week regimen for patients in whom HIV serostatus was unknown during the study period. Since August 1998, the NYC program has also recommended the 6-month regimen, in keeping with the national recommendations [27, 28] .
In summary, clinicians should be aware of the possibility of recurrence of positive cultures 6-9 months after the start of treatment among patients infected with HIV. Sputum evaluation to ensure cure or assessment 3 months after treatment completion should be performed among persons infected with HIV who receive the shorter regimen. The effect of the shorter regimen that is now recommended in NYC will require evaluation to determine its effect on patient outcomes.
